Loading...
Loading...
Few questions in venture finance generate more debate than how to value a startup. Unlike a public company with a market price updated every second, a private startup has no ticker, a thin financial history, and a future that ranges from zero to extraordinary. Yet valuation drives almost everything that matters to founders, employees, and investors — how much equity changes hands in a funding round, what your stock options are worth on paper, and how much of the company you actually own. This guide walks through the startup valuation methods that professional investors rely on, when each one applies, and what the numbers really mean for the equity sitting in your grant agreement.
Before diving in, one honest caveat from years spent on the investing side of the table: every startup valuation is an estimate dressed up as a number. The methods below bring discipline and comparability to that estimate, but none of them produces a single correct figure. The goal is a defensible range, not false precision — and anyone who tells you otherwise is selling something.
Traditional corporate finance assumes you can forecast cash flows and discount them back to today. Startups break that assumption. A seed-stage company may have no revenue at all; a Series A company may be deliberately burning cash to capture a market before competitors do. Standard metrics like price-to-earnings ratios are meaningless when there are no earnings. That is why startup valuation explained in plain terms is less about a single formula and more about triangulating across several imperfect approaches.
There is also a structural quirk worth understanding. The valuation quoted in headlines — say, a company raising at a $500 million post-money valuation — is not a market-clearing price for the whole company. It is the price one investor paid for one slice of preferred stock, with its own protective terms, multiplied across all shares as if every share were identical. Common shares held by employees usually sit below that preferred stock in the capital structure, which is why the 409A valuation of common stock is typically a meaningful discount to the headline number. The SEC's investor education resources explain why private-company shares carry these added layers of risk and illiquidity.
Practitioners lean on a handful of approaches, and which one dominates depends almost entirely on stage. For pre-revenue companies, qualitative scorecards rule. For growth-stage companies with real metrics, market comparables and forward-looking models take over. Below are the five startup valuation methods that show up most often in real deal rooms, roughly ordered from later stage to earliest stage. None is authoritative on its own; together they form a range.
Comparable company analysis — comps — is the workhorse of how to value a startup once it has real traction. The logic is simple: find recently funded or publicly traded companies that resemble the target in sector, growth rate, and business model, then apply their valuation multiples. Revenue multiples, such as enterprise value to forward revenue or enterprise value to annual recurring revenue for software, are the most common, because early companies rarely have profits to multiply.
A concrete example: if comparable B2B SaaS companies are raising at roughly ten times annual recurring revenue, and a startup has $8 million in ARR growing 120% year over year, a comps-based estimate lands somewhere around $80 million — adjusted up or down for growth rate, margins, and competitive position. The closely related last-round method simply anchors to the most recent financing: if a company raised twelve months ago at a $200 million post-money valuation and has executed well since, the next round is negotiated from that reference point. The 2022 to 2024 repricing of software multiples was a painful reminder that comps cut both ways — many startups that raised at 2021 peaks faced flat or down rounds once public comparables compressed.
When a startup has enough operating history to support a forecast, two forward-looking startup valuation methods come into play. Discounted cash flow, or DCF, projects free cash flows five to ten years out and discounts them back at a rate that reflects startup-level risk — often 30% to 60%, far above the discount rates used for mature public companies. DCF is intellectually rigorous but notoriously sensitive: small changes in the growth or discount assumptions swing the output dramatically, which is why experienced investors treat it as one input rather than the answer.
The venture capital method, popularized through Harvard Business School teaching materials, flips the logic. Instead of discounting cash flows, it starts at the exit: estimate what the company could be worth at acquisition or IPO, then work backward using the investor's target return — commonly ten times or more — to arrive at today's valuation. If a fund believes a company can exit for $1 billion and wants ten times its money on a five-year hold, the post-money valuation today needs to be around $100 million for that investment to pencil out. In my experience, this is the model most venture investors actually run in their heads, even when they cite comparable companies out loud.
For pre-revenue companies, there are no cash flows to discount and few clean comparables, so the earliest-stage startup valuation methods are deliberately qualitative. The Scorecard Method, sometimes called the Bill Payne method, starts with the average pre-money valuation of recently funded startups in the same region and stage, then adjusts up or down based on factors like team strength, market size, product, and competitive environment. The Berkus Method assigns a dollar value — traditionally capped at around $500,000 each — to five milestones: a sound idea, a working prototype, a quality management team, strategic relationships, and early product rollout. Risk Factor Summation works similarly, nudging a baseline value across roughly a dozen risk categories.
These methods can feel almost arbitrary, and to a degree they are. But they impose a useful checklist on what is otherwise pure negotiation, and they keep early valuations tethered to regional norms rather than founder optimism. Y Combinator's published guidance on standard seed terms is a helpful reality check on what early-stage valuation ranges actually look like in practice today.
With the major approaches covered, here is startup valuation explained from the equity holder's seat. The headline valuation sets the price of preferred stock; your common shares are valued separately, usually through a 409A appraisal that applies discounts for lack of marketability and for the liquidation preferences sitting ahead of you. Understanding the gap between those two numbers is essential before you exercise options or evaluate a job offer. Our guide on whether you should buy your equity walks through that decision in detail, and the Aption equity simulator lets you model outcomes across different exit scenarios.
It is also worth being honest about concentration. Even a carefully derived valuation is a single point estimate on one company whose real outcome distribution is enormously wide — most startups return little, and a few return almost everything. No valuation method changes that underlying risk profile; it only prices it. This is the core reason diversification matters so much for employees whose net worth is tied up in one logo, a tension we explore in why startup stock and option holders have a big problem.
No serious investor relies on a single approach. A typical process triangulates: comparables to establish a market-anchored range, the venture capital method to sanity-check that range against plausible exits, and a qualitative scorecard to adjust for team and traction. The methods converge into a negotiation range, and the final number is simply whatever a willing investor and a willing founder agree on. That is the honest version of startup valuation explained — disciplined estimation, not measurement.
For employees and early stakeholders, the takeaway is that you can and should interrogate the valuation behind your equity. Ask which method drove it, what comparable companies were used, and how your common stock relates to the preferred price. You do not need to be a finance professional to ask good questions — you only need to know that these methods exist and that each one carries assumptions worth challenging.
Learning how to value a startup is less about memorizing formulas and more about understanding which startup valuation methods apply at which stage — and treating every output as a range rather than a fact. Comparable company analysis, DCF, the venture capital method, and early-stage scorecards each capture part of the picture; none captures all of it. For founders, that knowledge sharpens fundraising conversations. For employees, it turns an abstract grant into something you can actually reason about.
It also reframes the bigger decision. Once you understand that any single startup valuation is one uncertain point on a very wide distribution, the case for spreading that risk becomes much clearer. Aption was built around exactly that idea — letting startup employees and stakeholders pool their equity for diversification rather than betting everything on one company's valuation holding up. If you want to see how that works, you can explore our introduction to equity pooling or get an offer to see real numbers for your own position.
The author name used in this article may be a pen name or pseudonym and is used for illustrative and editorial purposes only. This article is for informational purposes only and does not constitute investment, tax, or legal advice. Past performance and projected outcomes are not guarantees of future results, and startup valuations are inherently uncertain. Consult qualified professionals before making financial decisions.
Michael is a financial analyst and equity markets researcher who covers startup valuations, secondary markets, and alternative investment vehicles. He previously led equity research at a top-tier investment bank.